The effectiveness of CA125 and HE4 as clinical prognostic markers in epithelial ovarian cancer patients with BRCA mutation
CONCLUSION: Normalizing both biomarkers emerged as the most effective predictive marker for the 1-year recurrence rate, regardless of BRCA mutational status. A negative HE4 value can be a useful predictor for 1-year recurrence-free survival in patients with BRCA mutations.PMID:38670560 | DOI:10.3802/jgo.2024.35.e80 (Source: Journal of Gynecologic Oncology)
Source: Journal of Gynecologic Oncology - April 26, 2024 Category: OBGYN Authors: Young Joo Lee Woojin Kim Soomin Hong Yong Jae Lee Jung-Yun Lee Sang Wun Kim Sunghoon Kim Young Tae Kim Eun Ji Nam Source Type: research
Cost-effectiveness analysis of single-dose or 2-dose of bivalent, quadrivalent, or nonavalent HPV vaccine in a low/middle-income country setting
CONCLUSION: Oping for 2 doses of 9vHPV vaccine in conjunction with a primary HPV screening represents the most cost-effective option for implementing a school-based HPV vaccination program targeting 12-year-old girls in Thailand. Such findings provide valuable insights for policymakers in the realm of cervical cancer prevention.PMID:38670561 | DOI:10.3802/jgo.2024.35.e85 (Source: Journal of Gynecologic Oncology)
Source: Journal of Gynecologic Oncology - April 26, 2024 Category: OBGYN Authors: Wichai Termrungruanglert Nipon Khemapech Apichai Vasuratna Piyalamporn Havanond Tanitra Tantitamit Source Type: research
LncRNA STARD7-AS1 suppresses cervical cancer cell proliferation while promoting autophagy by regulating miR-31-5p/TXNIP axis to inactivate the mTOR signaling
CONCLUSION: In conclusion, lncRNA STARD7-AS1 inhibits CC cell proliferation and promotes cell autophagy by targeting the miR-31-5p/TXNIP axis to inactivate the mTOR signaling.PMID:38670562 | DOI:10.3802/jgo.2024.35.e97 (Source: Journal of Gynecologic Oncology)
Source: Journal of Gynecologic Oncology - April 26, 2024 Category: OBGYN Authors: Xiyao Yin Xin Liu Hui Gong Zhiliang Chu Source Type: research
Efficacy and safety of combined anlotinib-oral etoposide treatment for patients with platinum-resistant ovarian cancer
CONCLUSION: Anlotinib combined with etoposide emerged effective for the treatment of PROC.PMID:38670563 | DOI:10.3802/jgo.2024.35.e100 (Source: Journal of Gynecologic Oncology)
Source: Journal of Gynecologic Oncology - April 26, 2024 Category: OBGYN Authors: Shuai Huang Guihua Sheng Qiubo Lv Ye Li Qingwei Meng Xuexiao Gao Zhiyuan Shang Source Type: research
Women- and clinician- important outcomes and priorities regarding vasa praevia: An international qualitative study to inform development of a core outcome set
CONCLUSION: We have identified patient-important outcomes and experience measures that have been directly fed into the development of a core outcome set on vasa previa. Incorporating these considerations into both clinical practice and future research studies has the potential to improve outcomes and experiences for women with vasa praevia.PMID:38669723 | DOI:10.1016/j.wombi.2024.101614 (Source: Women Birth)
Source: Women Birth - April 26, 2024 Category: Midwifery Authors: Nasrin Javid Natasha Donnolley John Kingdom Rachel Dadouch Rohan D'Souza Source Type: research
